Business Context and Reporting Period
This Form 8-K filing by Cocrystal Pharma, Inc. was submitted on September 18, 2015, reporting events occurring between September 18 and September 21, 2015. The filing focuses on executive leadership transitions and new employment agreements for the Chief Executive Officer and Chief Medical Officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The financial data presented is limited to executive compensation terms:
- Jeffrey Meckler (CEO): Annual salary of $340,000; annual bonus up to 50% of base salary; grant of 16,000,000 stock options.
- Dr. Douglas Mayers (CMO): Annual salary of $280,000; annual bonus up to 35% of base salary; grant of 2,400,000 stock options.
Material Changes
The primary material change is the appointment of new principal officers:
- CEO Appointment: Jeffrey Meckler will transition from interim CEO to permanent CEO effective October 1, 2015.
- CMO Appointment: Dr. Douglas Mayers will be appointed Chief Medical Officer effective September 30, 2015.
Guidance, Outlook, and Risks
The filing contains no financial guidance, market outlook, or discussion of general business risks. The only contingencies noted are that the employment agreements are subject to ratification by the Company's board of directors and that employment is on an at-will basis. Stock option vesting is contingent upon continued employment and specific performance targets.
Investor Verification Checklist
- Confirm the Board of Directors has ratified the employment agreements for Jeffrey Meckler and Dr. Douglas Mayers.
- Verify the specific performance targets required to achieve the annual bonuses for both executives.
- Review the terms of the stock option grants (16 million for CEO, 2.4 million for CMO) for dilution impact on existing shareholders.
- Check subsequent filings for any updates on the company's cash position, as this 8-K does not disclose liquidity status.